Antitumour immunity gets a boost (Q59092145)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Cancer: Antitumour immunity gets a boost (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

Jedd D Wolchok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Timothy A Chan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

515

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

7528

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

496-498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunoediting: from immunosurveillance to tumor escape

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Immune modulation in cancer with antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2F515496A

The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25428495

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25428495

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/515496A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

23 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25428495%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

25428495

1 reference